

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,835	01/11/2001	Gabriele Multhoff	40740	1173
7	2590 03/27/2002			
Roylance Abrams Berdo & Goodman			EXAMINER	
Suite 600 1300 19th Stre	et NW	CANELLA, KAREN A		
Washington, DC 20036			ART UNIT	PAPER NUMBER
			1642	11
			DATE MAILED: 03/27/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

BEST AVAILABLE CL

Application No. 09/646,835 Applicant(s)

Multhoff Art Unit

Examiner

Karen Canella

1642



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

Office Action Summary

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 30 days MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will

- If NO co - Failur - Any i	mmunication. The to reply within the set or extended period for reply will,	ry period will apply and will expire SIX (6) MONTHS from the mailing date of this by statute, cause the application to become ABANDONED (35 U.S.C. § 133). the mailing date of this communication, even if timely filed, may reduce any			
Status					
1) 🗆	Responsive to communication(s) filed on				
2a) 🗌	This action is FINAL. 2b) 🗓 This action is non-final.				
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex p	e except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposi	ition of Claims				
4) 💢	Claim(s) <u>1-30</u>	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗌	Claim(s)	is/are allowed.			
6) 🗌	Claim(s)	is/are rejected.			
7) 🗌	Claim(s)	is/are objected to.			
8) 💢		are subject to restriction and/or election requirement.			
9) 🗆 10) 🗆	The specification is objected to by the Examiner. The drawing(s) filed on is/a	are objected to by the Examiner.			
	The proposed drawing correction filed on The oath or declaration is objected to by the Exa	is: a) approved b) disapproved.			
13) □ a) □	under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign All b)□ Some* c)□ None of: 1.□ Certified copies of the priority documents by Certified copies of the priority documents by				
	3. Copies of the certified copies of the priority application from the International Bute the attached detailed Office action for a list of	documents have been received in this National Stage ureau (PCT Rule 17.2(a)). the certified copies not received.			
14)	Acknowledgement is made of a claim for domes	tic priority under 35 U.S.C. § 119(e).			
Attachm	nent(s) otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).			
· —	otice of Heferences Cited (P10-892) otice of Draftsperson's Patent Drawing Review (PT0-948)	Notice of Informal Patent Application (PTO-152)			
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 20) Other:					

Art Unit: 1642

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-17, 24, 25 and 26-28, in part, drawn to use of Hsp70 to produce a pharmaceutical preparation, a method for ex vivo activation of NK cell comprising the administration of said preparation, and a pharmaceutical preparation comprising Hsp70.

Group II, claim(s) 18-23, 29, 30 and 26-28, in part, drawn to a method for the in vivo activation of the immune system comprising the administration of activated NK cells and use of the activated NK cells in the therapy of tumors or infectious diseases.

- 2. A national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)
- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

BEST AVAILABLE COPY

Application/Control Number: 09/646,835

Page 3

Art Unit: 1642

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner

can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may

be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application or proceeding should be

directed to the Group receptionist whose telephone number is (703) 308-0196.

Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

March 25, 2002

ANTHONY C. CAPUTA SUPERATIONAL PATENT EXAMINER TECHNICLUGY CENTER 1600

ans

BEST AVAILABLE COM